Sunday, 20 September 2026European Markets

BOUSSARD GAVAUDAN Stock Is 11% Up So Far On Tuesday

Loading stream...

BOUSSARD GAVAUDAN (AEX-Index: BGHL.AS) is experiencing noteworthy market movements. Shares of the France-based company rose 11.21% to EUR23.80 during trading Tuesday morning, marking a positive reaction in the market following three consecutive sessions of losses.

BGHL on AEX-Index Performance

Despite recent drawbacks, this closed-end balanced fund of funds listing on AEX-Index has shown relatively positive performance. Further highlighting its favourable performance is its increased listing value of 0.96% to EUR778.93, which is slightly offsetting its previous decrease.

Market Response to BOUSSARD GAVAUDAN's Performance

The positive development came after BOUSSARD GAVAUDAN closed at EUR21.40 on Monday, which is 10.83% lower than its 52-week high of EUR24.00. This indicates that the market response has partially alleviated its recent losses.

About BOUSSARD GAVAUDAN

BOUSSARD GAVAUDAN was established in October 2006 and specializes in value stocks of companies and fixed income securities from various sectors worldwide. They employ different strategies, including credit long/short positions and restructuring/distressed securities strategies among others, catering to a wide range of investor interests.

BOUSSARD GAVAUDAN's Bullish Trend

The financial institution has been trading above both its 50-day moving average of EUR21.81 and 200-day moving average of EUR22.17 for a prolonged period. This steady performance indicates a bullish trend in the near term. However, according to the stochastic oscillator, its overbought status could signal caution for investors considering buying at current prices.

Assessing BOUSSARD GAVAUDAN's Worth

Additionally, BOUSSARD GAVAUDAN reports a trailing twelve-month price to earnings ratio of 8.71. This indicates that investors are spending approximately EUR8.71 for every euro of annual earnings they currently generate, which can help potential buyers to determine its relative value.

Potential Concerns

However, it is essential to note that BOUSSARD GAVAUDAN's trailing twelve month return on equity (a key measure of profitability) is negative at -5.21%, indicating poor net asset management. Such a situation warrants diligent scrutiny before making investment decisions.

Investment Outlook

Despite recent fluctuations and market instability, the finance sector remains attractive with considerable growth and investment potential. It is crucial for Investors to have consumer financial literacy and profound knowledge of stock market dynamics to make informed investment decisions.

More news about BOUSSARD GAVAUDAN (BGHL.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com